Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2015

View Archived Issues

Chimeric oncolytic adenovirus improves shRNA delivery and tumor growth inhibiton

Collaborative research agreement signed for the development of antibody drug seeds

Prana Biotechnology's PBT-2 receives E.U. orphan drug designation for Huntington's disease

Development award to support Celtaxsys' phase II trial of CTX-4430 in cystic fibrosis

Phase III study of Sustol meets primary endpoint

MatinasBioPharma's MAT-9001 superior to Vascepa in reducing blood lipid levels

Results from an ongoing phase I study of DCR-M1711

Stemline Therapeutics releases topline results from lead-in stage of pivotal trial for SL-401

Systemic delivery of AAV-IFNb shows efficacy in the treatment of invasive glioblastoma

Phase I results reported for ulixertinib in advanced solid tumors

Neurovive discloses results from phase III trial of ciclosporin in STEMI

OPKO files NDA for Rayaldee for secondary hyperparathyroidism in CKD

Antisense Therapeutics announces expanded access program for ATL-1102 for MS

FDA accepts first sBLA for an immuno-oncology regimen

Genticel reports preclinical results for second-generation HPV vaccine GTL-002

University Health Network patents TTK inhibitors

Allergan patents S1P1 receptor agonists

Collaborative Medicinal Development develops metal complexes

BASF discloses oligopeptide apoptosis inhibitors

Tesaro to collaborate with Merck & Co., completes rolapitant bioequivalence study

MinervaX starts phase I trial of Group B Streptococcus vaccine

Arch enters R&D collaboration with CURAM

Phase I results for PQR-309 in advanced solid tumors pave way for phase II trial

Peregrine and Memorial Sloan Kettering Cancer Center to collaborate on antibody platform

Gilead submits sNDA for idelalisib plus ofatumumab

Redx Pharma discovers new antibacterial to combat MRSA

Meiji's ME-1100 gets FDA QIDP and fast track designations

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...